Frederick W Miller

List of Publications by Year
in descending order

244 papers	17,392 citations	11608 70 h-index	16605 123 g-index
251 all docs	251 docs citations	251 times ranked	10175 citing authors

#	Article	IF	Citations
1	Response to: â€˜Correspondence on â€˜EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroupsâ€™â€™ by Irfanet al. Annals of the Rheumatic Diseases, 2023, 82, e41-e41.	0.5	1
2	The Climate Emergency and the Health of Our Patients: The Role of the Rheumatologist. Arthritis and Rheumatology, 2023, 75, 1-3.	2.9	4
3	<scp>Antiâ€Cortactin</scp> Autoantibodies Are Associated With Key Clinical Features in Adult Myositis But Are Rarely Present in Juvenile Myositis. Arthritis and Rheumatology, 2022, 74, 358-364.	2.9	6
4	Association of anti-HSC70 autoantibodies with cutaneous ulceration and severe disease in juvenile dermatomyositis. Rheumatology, 2022, 61, 2969-2977.	0.9	6
5	Preliminary validation of muscle ultrasound in juvenile dermatomyositis (JDM). Rheumatology, 2022, 61, SI48-SI55.	0.9	6
6	Association with HLA-DRÎ²1 position 37 distinguishes juvenile dermatomyositis from adult-onset myositis. Human Molecular Genetics, 2022, 31, 2471-2481.	1.4	9
7	Hygiene Hypothesis Indicators and Prevalence of Antinuclear Antibodies in US Adolescents. Frontiers in Immunology, 2022, 13, 789379.	2.2	4
8	The origins, evolution and future of the International Myositis Assessment and Clinical Studies Group (IMACS). Clinical and Experimental Rheumatology, 2022, 40, 214-218.	0.4	1
9	The Geospatial Distribution of Myositis and Its Phenotypes in the United States and Associations With Roadways: Findings From a National Myositis Patient Registry. Frontiers in Medicine, 2022, 9, 842586.	1.2	2
10	<scp>47XXY</scp> and <scp>47XXX</scp> in Scleroderma and Myositis. ACR Open Rheumatology, 2022, 4, 528-533.	0.9	8
11	Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey. Rheumatology, 2022, 61, SI143-SI150.	0.9	40
12	Environmental factors associated with juvenile idiopathic inflammatory myopathy clinical and serologic phenotypes. Pediatric Rheumatology, 2022, 20, 28.	0.9	3
13	The origins, evolution and future of the International Myositis Assessment and Clinical Studies Group (IMACS).. Clinical and Experimental Rheumatology, 2022, 40, 214-218.	0.4	0
14	Defining anti-synthetase syndrome: a systematic literature review.. Clinical and Experimental Rheumatology, 2022, 40, 309-319.	0.4	1
15	Expanded assessment of xenobiotic associations with antinuclear antibodies in the United States, 1988â€“2012. Environment International, 2022, 166, 107376.	4.8	3
16	Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America. Rheumatology, 2021, 60, 1839-1849.	0.9	25
17	Slicing and dicing myositis for cures and prevention. Nature Reviews Rheumatology, 2021, 17, 255-256.	3.5	1
18	Anti-mitochondrial autoantibodies are associated with cardiomyopathy, dysphagia, and features of more severe disease in adult-onset myositis. Clinical Rheumatology, 2021, 40, 4095-4100.	1.0	14

#	Article	IF	Citations
19	A Biomedical Knowledge Graph System to Propose Mechanistic Hypotheses for Real-World Environmental Health Observations: Cohort Study and Informatics Application. JMIR Medical Informatics, 2021, 9, e26714.	1.3	10
20	HLA-DRB1 allelic epitopes that associate with autoimmune disease risk or protection activate reciprocal macrophage polarization. Scientific Reports, 2021, 11, 2599.	1.6	13
21	Idiopathic inflammatory myopathies. Nature Reviews Disease Primers, 2021, 7, 86.	18.1	212
22	Accumulation of autophagosome cargo protein p62 is common in idiopathic inflammatory myopathies. Clinical and Experimental Rheumatology, 2021, 39, 351-356.	0.4	2
23	Accumulation of autophagosome cargo protein p62 is common in idiopathic inflammatory myopathies. Clinical and Experimental Rheumatology, 2021, 39, 351-356.	0.4	8
24	Response to: â€˜Comment on: â€˜Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositisâ€™ by Sabbagh Set alâ€™by Yanget al. Annals of the Rheumatic Diseases, 2020, 79, e97-e97.	0.5	0
25	Long-term outcomes in Juvenile Myositis patients. Seminars in Arthritis and Rheumatism, 2020, 50, 149-155.	1.6	21
26	Endothelial Activation Markers as Disease Activity and Damage Measures in Juvenile Dermatomyositis. Journal of Rheumatology, 2020, 47, 1011-1018.	1.0	17
27	Association of Ultraviolet Radiation Exposure With Dermatomyositis in a National Myositis Patient Registry. Arthritis Care and Research, 2020, 72, 1636-1644.	1.5	19
28	Noninfectious Environmental Agents and Autoimmunity. , 2020, , 345-362.		2
29	Transethnic associations among immune-mediated diseases and single-nucleotide polymorphisms of the aryl hydrocarbon response gene ARNT and the PTPN22 immune regulatory gene. Journal of Autoimmunity, 2020, 107, 102363.	3.0	7
30	Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis. Annals of the Rheumatic Diseases, 2020, 79, 1234-1242.	0.5	80
31	Using the circulating proteome to assess type I interferon activity in systemic lupus erythematosus. Scientific Reports, 2020, 10, 4462.	1.6	13
32	Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies. Arthritis Research and Therapy, 2020, 22, 69.	1.6	39
33	Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies. JCI Insight, 2020, 5, .	2.3	65
34	Population-based estimates of humoral autoimmunity from the U.S. National Health and Nutrition Examination Surveys, 1960â€“2014. PLoS ONE, 2020, 15, e0226516.	1.1	15
35	Introduction to Myositis. , 2020, , 1-6.		0
36	Identification of distinctive interferon gene signatures in different types of myositis. Neurology, 2019, 93, e1193-e1204.	1.5	115

#	Article	IF	Citations
37	Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. Annals of the Rheumatic Diseases, 2019, 78, 996-1002.	0.5	81
38	Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Annals of the Rheumatic Diseases, 2019, 78, 988-995.	0.5	99
39	Risk factors and disease mechanisms in myositis. Nature Reviews Rheumatology, 2018, 14, 255-268.	3.5	108
40	The effect of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis. Seminars in Arthritis and Rheumatism, 2018, 48, 504-512.	1.6	36
41	Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis. Annals of the Rheumatic Diseases, 2018, 77, 714-719.	0.5	31
42	Medications received by patients with juvenile dermatomyositis. Seminars in Arthritis and Rheumatism, 2018, 48, 513-522.	1.6	16
43	A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis. Seminars in Arthritis and Rheumatism, 2018, 47, 858-864.	1.6	49
44	Prescription medication use and antinuclear antibodies in the United States, 1999â€“2004. Journal of Autoimmunity, 2018, 92, 93-103.	3.0	10
45	Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis. Rheumatology, 2018, 57, 1956-1963.	0.9	24
46	Association of Antiâ€“3â€Hydroxyâ€3â€Methylglutarylâ€Coenzyme A Reductase Autoantibodies With DRB1*07:01 and Severe Myositis in Juvenile Myositis Patients. Arthritis Care and Research, 2017, 69, 1088-1094.	1.5	71
47	Predictors of Reduced Healthâ€Related Quality of Life in Adult Patients With Idiopathic Inflammatory Myopathies. Arthritis Care and Research, 2017, 69, 1743-1750.	1.5	32
48	Environmental factors associated with disease flare in juvenile and adult dermatomyositis. Rheumatology, 2017, 56, 1342-1347.	0.9	46
49	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2017, 69, 911-923.	2.9	59
50	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2017, 69, 898-910.	2.9	52
51	2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis. Annals of the Rheumatic Diseases, 2017, 76, 792-801.	0.5	92
52	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis. Annals of the Rheumatic Diseases, 2017, 76, 782-791.	0.5	51
53	2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Annals of the Rheumatic Diseases, 2017, 76, 1955-1964.	0.5	754
54	EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open, 2017, 3, e000507.	1.8	115

#	Article	IF	Citations
55	2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis and Rheumatology, 2017, 69, 2271-2282.	2.9	391
56	The Association of Arsenic Exposure and Metabolism With Type 1 and Type 2 Diabetes in Youth: The SEARCH Case-Control Study. Diabetes Care, 2017, 40, 46-53.	4.3	61
57	2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteriaâ€"methodological aspects. Rheumatology, 2017, 56, 1884-1893.	0.9	33
58	Antinuclear antibodies and mortality in the National Health and Nutrition Examination Survey (1999-2004). PLoS ONE, 2017, 12, e0185977.	1.1	9
59	Magnetic resonance measurement of muscle T2, fat-corrected T2 and fat fraction in the assessment of idiopathic inflammatory myopathies. Rheumatology, 2016, 55, kev344.	0.9	41
60	Associations Between Selected Xenobiotics and Antinuclear Antibodies in the National Health and Nutrition Examination Survey, 1999â€"2004. Environmental Health Perspectives, 2016, 124, 426-436.	2.8	27
61	Brief Report: Association of Myositis Autoantibodies, Clinical Features, and Environmental Exposures at Illness Onset With Disease Course in Juvenile Myositis. Arthritis and Rheumatology, 2016, 68, 761-768.	2.9	43
62	CD3Zhypermethylation is associated with severe clinical manifestations in systemic lupus erythematosus and reduces CD3Î¶-chain expression in T cells. Rheumatology, 2016, 56, kew405.	0.9	12
63	Muscle myeloid type I interferon gene expression may predict therapeutic responses to rituximab in myositis patients. Rheumatology, 2016, 55, 1673-1680.	0.9	11
64	Diagnosis and classification of idiopathic inflammatory myopathies. Journal of Internal Medicine, 2016, 280, 39-51.	2.7	134
65	Juvenile Dermatomyositis. , 2016, , 351-383.e18.		22
66	Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. Annals of the Rheumatic Diseases, 2016, 75, 1558-1566.	0.5	127
67	Gene copy-number variations (CNVs) of complement C4 and C4A deficiency in genetic risk and pathogenesis of juvenile dermatomyositis. Annals of the Rheumatic Diseases, 2016, 75, 1599-1606.	0.5	36
68	Chimeric cells of maternal origin do not appear to be pathogenic in the juvenile idiopathic inflammatory myopathies or muscular dystrophy. Arthritis Research and Therapy, 2015, 17, 238.	1.6	6
69	Gene Expression Profiles from Disease Discordant Twins Suggest Shared Antiviral Pathways and Viral Exposures among Multiple Systemic Autoimmune Diseases. PLoS ONE, 2015, 10, e0142486.	1.1	16
70	Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes. Genes and Immunity, 2015, 16, 470-480.	2.2	103
71	Management of inflammatory muscle disease. , 2015, , 1248-1254.		1
72	Consensus statement on screening, diagnosis, classification and treatment of endemic (Balkan) nephropathy. Nephrology Dialysis Transplantation, 2014, 29, 2020-2027.	0.4	48

#	Article	IF	Citations
73	Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Thorax, 2014, 69, 436-444.	2.7	100
74	A58: Demographics, Clinical Features and Therapies of Patients with Juvenile Dermatomyositis Participating in a National Myositis Patient Registry. Arthritis and Rheumatology, 2014, 66, S86-S87.	2.9	3
75	Accommodating Measurements Below a Limit of Detection: A Novel Application of Cox Regression. American Journal of Epidemiology, 2014, 179, 1018-1024.	1.6	42
76	Myositis registries and biorepositories. Current Opinion in Rheumatology, 2014, 26, 724-741.	2.0	16
77	Expert Panel Workshop Consensus Statement on the Role of the Environment in the Development of Autoimmune Disease. International Journal of Molecular Sciences, 2014, 15, 14269-14297.	1.8	100
78	Reproductive and Hormonal Risk Factors for Antinuclear Antibodies (ANA) in a Representative Sample of U.S. Women. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2492-2502.	1.1	27
79	Non-infectious Environmental Agents and Autoimmunity. , 2014, , 283-295.		1
80	A47: Progress Report on the Development of New Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies. Arthritis and Rheumatology, 2014, 66, S70-S71.	2.9	14
81	Early Illness Features Associated With Mortality in the Juvenile Idiopathic Inflammatory Myopathies. Arthritis Care and Research, 2014, 66, 732-740.	1.5	68
82	Idiopathic inflammatory myopathies and the anti-synthetase syndrome: A comprehensive review. Autoimmunity Reviews, 2014, 13, 367-371.	2.5	233
83	A25: The Association of Immunogenetic and Environmental Factors with Disease Course in Patients with Juvenile Idiopathic Inflammatory Myopathies. Arthritis and Rheumatology, 2014, 66, S39-S40.	2.9	1
84	Predictors of Clinical Improvement in Rituximabâ€Treated Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis. Arthritis and Rheumatology, 2014, 66, 740-749.	2.9	210
85	Twins discordant for myositis and systemic lupus erythematosus show markedly enriched autoantibodies in the affected twin supporting environmental influences in pathogenesis. BMC Musculoskeletal Disorders, 2014, 15, 67.	0.8	18
86	Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial. Clinical and Experimental Rheumatology, 2014, 32, 689-96.	0.4	14
87	Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placeboâ€phase trial. Arthritis and Rheumatism, 2013, 65, 314-324.	6.7	514
88	Genomeâ€Wide Association Study of Dermatomyositis Reveals Genetic Overlap With Other Autoimmune Disorders. Arthritis and Rheumatism, 2013, 65, 3239-3247.	6.7	113
89	The Myositis Autoantibody Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies. Medicine (United States), 2013, 92, 223-243.	0.4	224
90	Brief Report: Ultraviolet Radiation Exposure Is Associated With Clinical and Autoantibody Phenotypes in Juvenile Myositis. Arthritis and Rheumatism, 2013, 65, 1934-1941.	6.7	58

#	Article	IF	Citations
91	Childhood socioeconomic factors and perinatal characteristics influence development of rheumatoid arthritis in adulthood. Annals of the Rheumatic Diseases, 2013, 72, 350-356.	0.5	41
92	Clinical and Laboratory Features Distinguishing Juvenile Polymyositis and Muscular Dystrophy. Arthritis Care and Research, 2013, 65, 1969-1975.	1.5	21
93	The Clinical Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies. Medicine (United States), 2013, 92, 25-41.	0.4	145
94	Post-Zygotic and Inter-Individual Structural Genetic Variation in a Presumptive Enhancer Element of the Locus between the IL10RÎ² and IFNAR1 Genes. PLoS ONE, 2013, 8, e67752.	1.1	2
95	Criteria for environmentally associated autoimmune diseases. Journal of Autoimmunity, 2012, 39, 253-258.	3.0	113
96	Epidemiology of environmental exposures and human autoimmune diseases: Findings from a National Institute of Environmental Health Sciences Expert Panel Workshop. Journal of Autoimmunity, 2012, 39, 259-271.	3.0	288
97	New approaches to the assessment and treatment of the idiopathic inflammatory myopathies. Annals of the Rheumatic Diseases, 2012, 71, i82-i85.	0.5	57
98	Polymyositis and Dermatomyositis. , 2012, , 1716-1720.		3
99	Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis and Rheumatism, 2012, 64, 2319-2327.	6.7	338
100	Age-Related Somatic Structural Changes in the Nuclear Genome of Human Blood Cells. American Journal of Human Genetics, 2012, 90, 217-228.	2.6	168
101	Laboratory Test Abnormalities are Common in Polymyositis and Dermatomyositis and Differ Among Clinical and Demographic Groups. Open Rheumatology Journal, 2012, 6, 54-63.	0.1	48
102	Mass Spectrometric Determination of IgG Subclass-Specific Glycosylation Profiles in Siblings Discordant for Myositis Syndromes. Journal of Proteome Research, 2011, 10, 2969-2978.	1.8	35
103	Plasma proteomic profiles from disease-discordant monozygotic twins suggest that molecular pathways are shared in multiple systemic autoimmune diseases*. Arthritis Research and Therapy, 2011, 13, R181.	1.6	13
104	Gene expression profiles from discordant monozygotic twins suggest that molecular pathways are shared among multiple systemic autoimmune diseases. Arthritis Research and Therapy, 2011, 13, R69.	1.6	37
105	State of the art. Current Opinion in Rheumatology, 2011, 23, 585-594.	2.0	31
106	Xenotropic murine leukemia virus-related virus is not associated with chronic fatigue syndrome in patients from different areas of the us in the 1990s. Virology Journal, 2011, 8, 450.	1.4	6
107	Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (Câ€HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SFâ€36), Child Health Questionnaire (CHQ), Physician Global Damage, Myositis Damage Index (MDI), Quantitative Muscle T. Arthritis Care and Research, 2011, 63, S118-57.	1.5	288
108	Postâ€epidemic eosinophiliaâ€“myalgia syndrome associated with Lâ€tryptophan. Arthritis and Rheumatism, 2011, 63, 3633-3639.	6.7	61

#	Article	IF	Citations
109	Environmental Agents and Autoimmune Diseases. Advances in Experimental Medicine and Biology, 2011, 711, 61-81.	0.8	36
110	Deciphering the Clinical Presentations, Pathogenesis, and Treatment of the Idiopathic Inflammatory Myopathies. JAMA - Journal of the American Medical Association, 2011, 305, 183.	3.8	115
111	Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care and Research, 2010, 62, 465-472.	1.5	204
112	Mast cells and type I interferon responses in the skin of patients with juvenile dermatomyositis: Are current therapies just scratching the surface?. Arthritis and Rheumatism, 2010, 62, 2619-2622.	6.7	3
113	Environmental factors preceding illness onset differ in phenotypes of the juvenile idiopathic inflammatory myopathies. Rheumatology, 2010, 49, 2381-2390.	0.9	44
114	Inhibitor of NF-Î¹B Kinases Î± and Î² Are Both Essential for High Mobility Group Box 1-Mediated Chemotaxis. Journal of Immunology, 2010, 184, 4497-4509.	0.4	90
115	Correction: Inhibitor Of Nk-Î¹B Kinases Î± And Î² Are Both Essential for High Mobility Group Box 1-Mediated Chemotaxis. Journal of Immunology, 2010, 184, 7314-7314.	0.4	1
116	Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Research, 2010, 20, 170-179.	2.4	569
117	Metabolic Abnormalities and Cardiovascular Risk Factors in Children with Myositis. Journal of Pediatrics, 2009, 155, 882-887.	0.9	27
118	HLA type and immune response to Borrelia burgdorferi outer surface protein a in people in whom arthritis developed after Lyme disease vaccination. Arthritis and Rheumatism, 2009, 60, 1179-1186.	6.7	44
119	Immunogenetic risk and protective factors for the development of Lâ€tryptophanâ€“associated eosinophiliaâ€“myalgia syndrome and associated symptoms. Arthritis and Rheumatism, 2009, 61, 1305-1311.	6.7	18
120	Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and antiâ€“Miâ€2 autoantibodies in women. Arthritis and Rheumatism, 2009, 60, 2499-2504.	6.7	130
121	Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis and Rheumatism, 2009, 60, 3425-3435.	6.7	107
122	Genetic risk and protective factors for the idiopathic inflammatory myopathies. Current Rheumatology Reports, 2009, 11, 287-294.	2.1	19
123	Inflammatory Myopathies. , 2009, , 191-199.		0
124	Microstructure and mineral composition of dystrophic calcification associated with the idiopathic inflammatory myopathies. Arthritis Research and Therapy, 2009, 11, R159.	1.6	36
125	On Determining the Effects of Therapy on Disease Damage in Non Randomized Studies with Multiple Treatments: A Study of Juvenile Myositis. Communications in Statistics - Theory and Methods, 2009, 38, 3268-3281.	0.6	0
126	Classification of Idiopathic Inflammatory Myopathies. , 2009, , 15-28.		6

#	Article	IF	Citations
127	Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatology Online Journal, 2009, 15, 1.	0.2	13
128	Review of the classification and assessment of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatology Online Journal, 2009, 15, 2.	0.2	10
129	Alternative scoring of the cutaneous assessment tool in juvenile dermatomyositis: Results using abbreviated formats. Arthritis and Rheumatism, 2008, 59, 352-356.	6.7	37
130	Preliminary validation and clinical meaning of the cutaneous assessment tool in juvenile dermatomyositis. Arthritis and Rheumatism, 2008, 59, 214-221.	6.7	51
131	Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies. Arthritis and Rheumatism, 2008, 58, 3239-3246.	6.7	43
132	Applicability of the paediatric rheumatology international trials organisation disease activity core set for juvenile dermatomyositis: Comment on the article by Ruperto et al. Arthritis and Rheumatism, 2008, 59, 1197-1198.	6.7	2
133	Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis and Rheumatism, 2008, 58, 3941-3950.	6.7	80
134	UV Radiation Regulates Mi-2 through Protein Translation and Stability. Journal of Biological Chemistry, 2008, 283, 34976-34982.	1.6	54
135	Predictors of Acquired Lipodystrophy in Juvenile-Onset Dermatomyositis and a Gradient of Severity. Medicine (United States), 2008, 87, 70-86.	0.4	137
136	Idiopathic Inflammatory Myopathies. , 2008, , 368-374.		45
137	Developing international consensus on measures of improvement for patients with myositis. Statistical Methods in Medical Research, 2007, 16, 51-64.	0.7	5
138	Serum proteins and paraproteins in women with silicone implants and connective tissue disease: a caseâ€“control study. Arthritis Research and Therapy, 2007, 9, R95.	1.6	6
139	Mechanisms of Disease: environmental factors in the pathogenesis of rheumatic disease. Nature Clinical Practice Rheumatology, 2007, 3, 172-180.	3.2	72
140	Seasonal birth patterns in myositis subgroups suggest an etiologic role of early environmental exposures. Arthritis and Rheumatism, 2007, 56, 2719-2728.	6.7	55
141	Late-onset gastrointestinal pain in juvenile dermatomyositis as a manifestation of ischemic ulceration from chronic endarteropathy. Arthritis and Rheumatism, 2007, 57, 881-884.	6.7	55
142	Human autoantibodies against the 54 kDa protein of the signal recognition particle block function at multiple stages. Arthritis Research and Therapy, 2006, 8, R39.	1.6	47
143	Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report. Biology of Blood and Marrow Transplantation, 2006, 12, 252-266.	2.0	445
144	A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis and Rheumatism, 2006, 54, 3682-3689.	6.7	418

#	Article	IF	Citations
145	HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: Allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis and Rheumatism, 2006, 54, 3670-3681.	6.7	78
146	Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. Arthritis and Rheumatism, 2006, 54, 3979-3987.	6.7	66
147	Immunogenetic Risk and Protective Factors for the Idiopathic Inflammatory Myopathies. Medicine (United States), 2006, 85, 111-127.	0.4	140
148	Is occupational exposure to mineral oil a risk factor for rheumatoid arthritis?. Nature Clinical Practice Rheumatology, 2006, 2, 130-131.	3.2	1
149	Virus-mediated autoimmunity in Multiple Sclerosis. Journal of Autoimmune Diseases, 2006, 3, 1.	1.0	33
150	Endothelial cell activation and neovascularization are prominent in dermatomyositis. Journal of Autoimmune Diseases, 2006, 3, 2.	1.0	69
151	Noninfectious Environmental Agents and Autoimmunity. , 2006, , 297-307.		3
152	Immunogenetic Risk and Protective Factors for the Idiopathic Inflammatory Myopathies. Medicine (United States), 2005, 84, 338-349.	0.4	92
153	Seasonal influence on the onset of idiopathic inflammatory myopathies in serologically defined groups. Arthritis and Rheumatism, 2005, 52, 2433-2438.	6.7	60
154	International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis and Rheumatism, 2005, 52, 2607-2615.	6.7	146
155	Clinical Presentation and Therapy of Idiopathic Inflammatory Myopathies. Journal of Musculoskeletal Pain, 2004, 12, 85-91.	0.3	2
156	Possible roles and determinants of microchimerism in autoimmune and other disorders. Autoimmunity Reviews, 2004, 3, 454-463.	2.5	39
157	Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis and Rheumatism, 2004, 50, 1595-1603.	6.7	195
158	International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis and Rheumatism, 2004, 50, 2281-2290.	6.7	202
159	Normal scores for nine maneuvers of the Childhood Myositis Assessment Scale. Arthritis and Rheumatism, 2004, 51, 365-370.	6.7	41
160	Immunogenetic differences between Caucasian women with and those without silicone implants in whom myositis develops. Arthritis and Rheumatism, 2004, 50, 3646-3650.	6.7	27
161	Autoantibodies as Predictive and Diagnostic Markers of Idiopathic Inflammatory Myopathies. Autoimmunity, 2004, 37, 291-294.	1.2	15
162	Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis and Rheumatism, 2003, 48, 2285-2293.	6.7	167

#	Article	IF	Citations
163	HLA-DQA1 is not an apparent risk factor for microchimerism in patients with various autoimmune diseases and in healthy individuals. Arthritis and Rheumatism, 2003, 48, 2567-2572.	6.7	37
164	Diagnostic criteria for polymyositis and dermatomyositis. Lancet, The, 2003, 362, 1762-1763.	6.3	67
165	Defining Clinical Improvement in Adult and Juvenile Myositis. Journal of Rheumatology, 2003, 30, 603-17.	1.0	124
166	Genomic organization, transcriptional mapping, and evolutionary implications of the human bi-directional histidyl-tRNA synthetase locus (HARS/HARSL). Biochemical and Biophysical Research Communications, 2002, 294, 609-614.	1.0	11
167	Occupational exposures and autoimmune diseases. International Immunopharmacology, 2002, 2, 303-313.	1.7	135
168	Idiopathic inflammatory myopathies. Rheumatic Disease Clinics of North America, 2002, 28, xi-xiii.	0.8	3
169	Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: Ethnogeographic influences in the genetics and clinical expression of myositis. Arthritis and Rheumatism, 2002, 46, 1885-1893.	6.7	86
170	Approaches to risk assessment of immunotoxic effects of chemicalsâ˜†. Toxicology, 2001, 161, 213-228.	2.0	8
171	Update on the genetics of the idiopathic inflammatory myopathies. Current Opinion in Rheumatology, 2000, 12, 482-491.	2.0	86
172	Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis and Rheumatism, 2000, 43, 243.	6.7	82
173	Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis: Implications for diagnosis and therapy. Arthritis and Rheumatism, 2000, 43, 1866-1873.	6.7	132
174	Polymorphisms in the IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies. Clinical and Experimental Immunology, 2000, 121, 47-52.	1.1	69
175	Idiopathic inflammatory muscle disease: clinical aspects. Best Practice and Research in Clinical Rheumatology, 2000, 14, 37-54.	1.4	42
176	Familial autoimmunity and the idiopathic inflammatory myopathies. Current Rheumatology Reports, 2000, 2, 201-211.	2.1	30
177	Restricted and Shared Patterns of TCR Î²-chain Gene Expression in Silicone Breast Implant Capsules and Remote Sites of Tissue Inflammation. Journal of Autoimmunity, 2000, 14, 283-293.	3.0	4
178	Chimeric cells of maternal origin in juvenile idiopathic inflammatory myopathies. Lancet, The, 2000, 356, 2155-2156.	6.3	173
179	Genetic risk and protective factors for idiopathic inflammatory myopathy in Koreans and American Whites: A tale of two loci. Arthritis and Rheumatism, 1999, 42, 1285-1290.	6.7	58
180	Novel gastrointestinal tract manifestations in juvenile dermatomyositis. Journal of Pediatrics, 1999, 135, 371-374.	0.9	42

#	Article	IF	Citations
181	The Role of Genetic Factors in Autoimmune Disease: Implications for Environmental Research. Environmental Health Perspectives, 1999, 107, 693.	2.8	29
182	Treatment of refractory myositis: A randomized crossover study of two new cytotoxic regimens. Arthritis and Rheumatism, 1998, 41, 392-399.	6.7	166
183	Familial autoimmunity in pedigrees of idiopathic inflammatory myopathy patients suggests common genetic risk factors for many autoimmune diseases. Arthritis and Rheumatism, 1998, 41, 400-405.	6.7	84
184	Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy. Arthritis and Rheumatism, 1998, 41, 710-719.	6.7	65
185	Myositis and myopathies. Current Opinion in Rheumatology, 1998, 10, 499-503.	2.0	1
186	Understanding Cancer: From Basic Science to Clinical Practice.Malcolm R. Alison , Catherine E. Sarraf. Quarterly Review of Biology, 1998, 73, 253-253.	0.0	0
187	Annual Review of Immunology. Volume 15: 1997.William E. Paul , C. Garrison Fathman , Henry Metzger. Quarterly Review of Biology, 1998, 73, 254-255.	0.0	0
188	Classification criteria for the idiopathic inflammatory myopathies. Current Opinion in Rheumatology, 1997, 9, 527-535.	2.0	227
189	CLASSIFICATION AND TREATMENT OF THE JUVENILE IDIOPATHIC INFLAMMATORY MYOPATHIES. Rheumatic Disease Clinics of North America, 1997, 23, 619-655.	0.8	128
190	Clinical, serologic, and immunogenetic features in polish patients with idiopathic inflammatory myopathies. Arthritis and Rheumatism, 1997, 40, 1257-1266.	6.7	4
191	Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. I. Physician, parent, and patient global assessments. Arthritis and Rheumatism, 1997, 40, 1976-1983.	6.7	127
192	Clinical, serologic, and immunogenetic features in polish patients with idiopathic inflammatory myopathies. Arthritis and Rheumatism, 1997, 40, 1257-1266.	6.7	135
193	Molecular Immunology. Volume 11.B. David Hames , David M. Glover. Quarterly Review of Biology, 1997, 72, 507-507.	0.0	1
194	Myositis and myopathies. Current Opinion in Rheumatology, 1996, 8, 491-494.	2.0	1
195	Focal myositis presenting as pseudothrombophlebitis of the neck in a patient with mixed connective tissue disease. Arthritis and Rheumatism, 1996, 39, 1254-1258.	6.7	12
196	Signal Recognition Particle Autoantibodies. , 1996, , 735-740.		0
197	T cell-mediated immune mechanisms in myositis. Current Opinion in Rheumatology, 1995, 7, 503-509.	2.0	12
198	Myositis: Immunologic Contributions to Understanding Cause, Pathogenesis, and Therapy. Annals of Internal Medicine, 1995, 122, 715.	2.0	150

#	Article	IF	Citations
199	Genetics of Autoimmune Diseases. , 1995, 12, 182-190.		11
200	A broadened spectrum of juvenile myositis. myositis-specific autoantibodies in children. Arthritis and Rheumatism, 1994, 37, 1534-1538.	6.7	96
201	Chronic Beryllium Diseaseâ€"From the Workplace to Cellular Immunology, Molecular Immunogenetics, and Back. Clinical Immunology and Immunopathology, 1994, 71, 123-129.	2.1	57
202	The Î±Î² T-Cell Receptor Repertoire in Inclusion Body Myositis: Diverse Patterns of Gene Expression by Muscle-infiltrating Lymphocytes. Journal of Autoimmunity, 1994, 7, 321-333.	3.0	41
203	New perspectives on the idiopathic inflammatory myopathies of childhood. Current Opinion in Rheumatology, 1994, 6, 575-582.	2.0	10
204	CLASSIFICATION AND PROGNOSIS OF INFLAMMATORY MUSCLE DISEASE. Rheumatic Disease Clinics of North America, 1994, 20, 811-826.	0.8	41
205	Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. American Journal of Medicine, 1993, 94, 379-387.	0.6	283
206	Myositis-Specific Autoantibodies. JAMA - Journal of the American Medical Association, 1993, 270, 1846.	3.8	79
207	The Treatment of Inclusion Body Myositis. Medicine (United States), 1993, 72, 225-235.	0.4	101
208	Noninfectious environmental agents associated with myopathies. Current Opinion in Rheumatology, 1993, 5, 712-718.	2.0	36
209	Controlled Trial of Plasma Exchange and Leukapheresis in Polymyositis and Dermatomyositis. New England Journal of Medicine, 1992, 326, 1380-1384.	13.9	320
210	Viruses in idiopathic inflammatory myopathies: absence of candidate viral genomes in muscle. Lancet, The, 1992, 339, 1192-1195.	6.3	140
211	Simultaneous onset of systemic sclerosis (scleroderma) and lung cancer: A case report and histologic analysis of fibrogenic peptides. American Journal of Medicine, 1992, 92, 705-708.	0.6	16
212	Antibodies to glycylâ€"transfer rna synthetase in patients with myositis and interstitial lung disease. Arthritis and Rheumatism, 1992, 35, 821-830.	6.7	98
213	The Neuromuscular Pathology of the Eosinophilia-Myalgia Syndrome. Journal of Neuropathology and Experimental Neurology, 1991, 50, 49-62.	0.9	31
214	Humoral immunity and immunogenetics in the idiopathic inflammatory myopathies. Current Opinion in Rheumatology, 1991, 3, 902-910.	2.0	27
215	Thyroid Stimulating and Thyrotrophin Binding-Inhibitory Immunoglobulin Activity in Patients with Systemic Lupus Erythematosus Having Thyroid Function Abnormalities. Thyroid, 1991, 1, 229-234.	2.4	11
216	A New Approach to the Classification of Idiopathic Inflammatory Myopathy. Medicine (United States), 1991, 70, 360-374.	0.4	889

#	Article	IF	Citations
217	Distinct seasonal patterns in the onset of adult idiopathic inflammatory myopathy in patients with antiâ€joâ€1 and antiâ€signal recognition particle autoantibodies. Arthritis and Rheumatism, 1991, 34, 1391-1396.	6.7	97
218	Antibody to signal recognition particle in polymyositis. Arthritis and Rheumatism, 1990, 33, 1361-1370.	6.7	283
219	Polymyositis/dermatomyositis associated with dermatitis herpetiformis. Arthritis and Rheumatism, 1989, 32, 1179-1181.	6.7	15
220	Current Concepts in the Idiopathic Inflammatory Myopathies: Polymyositis, Dermatomyositis, and Related Disorders. Annals of Internal Medicine, 1989, 111, 143.	2.0	279
221	Stimulation and partial stabilization of human histidyl-tRNA synthetase by hemoglobin. FEBS Letters, 1988, 229, 203-205.	1.3	3
222	An efficient method for enrichment of histidyl-tRNA synthetase (Jo-1 antigen) from HeLa cells. Journal of Immunological Methods, 1987, 98, 235-241.	0.6	7
223	An enzyme-linked immunosorbent assay for the detection and quantitation of anti-Jo-1 antibody in human serum. Journal of Immunological Methods, 1987, 98, 243-248.	0.6	33
224	Viral and host genetic factors influence encephalomyocarditis virusâ€”induced polymyositis in adult mice. Arthritis and Rheumatism, 1987, 30, 549-556.	6.7	38
225	Prevalence of thyroid disease and abnormal thyroid function test results in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 1987, 30, 1124-1130.	6.7	108
226	Induction of bone by xenografts of rabbit growth plate chondrocytes in the nude mouse. Calcified Tissue International, 1985, 37, 250-256.	1.5	21
227	Evidence for major differences in ribosomal subunit proteins from Plasmodium berghei and rat liver. Molecular and Biochemical Parasitology, 1984, 12, 249-260.	0.5	3
228	Disaccharidase values in iron-deficient infants. Journal of Pediatrics, 1981, 99, 605-608.	0.9	12
229	<italic>N</italic>,<italic>N</italic>-Dimethylformamide-Induced Modulation of Organ- and Tumor-Associated Markers in Cultured Human Colon Carcinoma Cells<xref ref-type="fn" rid="FN2">2</xref><xref ref-type="fn" rid="FN3">3</xref>. Journal of the National Cancer Institute, 1980, . . .	3.0	17
230	A Mucoprotein with Colonâ€Specific Determinants. Tissue Antigens, 1978, 11, 362-371.	1.0	18
231	Antibodies in Human Diagnosis and Therapy.Edgar Haber , Richard M. Krause. Quarterly Review of Biology, 1978, 53, 81-81.	0.0	0
232	The Immunopathophysiological Effects of Chronic Serum Sickness on Rat Choroid Plexus, Ciliary Process and Renal Glomeruli. Journal of Neuropathology and Experimental Neurology, 1977, 36, 726-733.	0.9	29
233	Serum-Derived Immunosuppressive Substances. International Archives of Allergy and Immunology, 1977, 55, 239-246.	0.9	2
234	Serum-Derived Immunosuppressive Substances. International Archives of Allergy and Immunology, 1977, 55, 228-238.	0.9	3

#	Article	IF	Citations
235	Failure of cobra venom factor to inhibit antigen-induced arthritis. Arthritis and Rheumatism, 1977, 20, 1567-1567.	6.7	3
236	Application of immunologic probes for contractile proteins to tissue sections. Clinical Immunology and Immunopathology, 1976, 5, 416-428.	2.1	12
237	SERUM-DERIVED IMMUNOSUPPRESSIVE SUBSTANCES. Transplantation, 1976, 21, 179-187.	0.5	29
238	Chemical and immunological differences between normal and tumoral colonic mucoprotein antigen. Nature, 1975, 255, 85-87.	13.7	34
239	The effect of specific glycosidase treatment on the responsiveness of lymphocytes. Cellular Immunology, 1974, 10, 136-144.	1.4	2
240	Characterization of human colonic mucoprotein antigen. Immunochemistry, 1974, 11, 369-375.	1.3	47
241	Preliminary evidence for the structure of the concanavalin-A binding site on human lymphocytes that induces mitogenesis. Cellular Immunology, 1973, 6, 132-139.	1.4	21
242	Glycopeptides of human immunoglobulinsâ€”III. Immunochemistry, 1972, 9, 217-228.	1.3	26
243	Glycopeptides of human immunoglobulinsâ€”II contribution to the antigenicity of the heavy chain. Immunochemistry, 1971, 8, 99-111.	1.3	7
244	Glycopeptides of human immunoglobulinsâ€”I preparation and carbohydrate composition. Immunochemistry, 1970, 7, 423-436.	1.3	12